Drugs / TLPLDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02301611 | Jan 2015 → May 2022 | melanoma | Elios Therapeutics, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2020-02-07 | Elios Therapeutics, LLC | Results New Phase IIb Data for Personalized Cancer Vaccine in High-Risk Melanoma Patients eliostherapeutics.com ↗ |
| 2019-11-21 | Elios Therapeutics, LLC | Results Personalized Cancer Vaccine Significantly Reduces Risk of Melanoma Recurrence in High-Risk Patients eliostherapeutics.com ↗
Elios Therapeutics Presents Primary Analysis of Phase IIb Study Showing Personalized Cancer Vaccine Significantly Reduces Risk of Melanoma Recurrence in High-Risk Patients |
| 2019-07-17 | Elios Therapeutics, LLC | Results Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC eliostherapeutics.com ↗ |
| 2018-06-01 | Elios Therapeutics, LLC | Results Interim Phase IIb Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine eliostherapeutics.com ↗
In the per treatment population, TLPLDC showed a meaningful 32 percent reduction in the relative risk of recurrence (TLPLDC 29.4 percent vs. placebo 43.3 percent, p = 0.07) with a median follow-up of 12.6 months. |
| 2018-04-17 | Elios Therapeutics, LLC | Results Initial Phase 2b Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine... eliostherapeutics.com ↗
Elios Therapeutics, a biopharmaceutical company developing innovative particle-delivered, dendritic cell vaccines in oncology, today presented initial open-label results from the ongoing Phase 2b clinical trial of the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine in patients with stage III and IV (resected) melanoma. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-07 | Elios Therapeutics, LLC | New Phase IIb Data for Personalized Cancer Vaccine in High-Risk Melanoma Patients eliostherapeutics.com ↗ |
| 2019-11-21 | Elios Therapeutics, LLC | Personalized Cancer Vaccine Significantly Reduces Risk of Melanoma Recurrence in High-Risk Patients eliostherapeutics.com ↗ |
| 2019-07-17 | Elios Therapeutics, LLC | Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC eliostherapeutics.com ↗ |
| 2018-06-01 | Elios Therapeutics, LLC | Interim Phase IIb Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine eliostherapeutics.com ↗ |
| 2018-04-17 | Elios Therapeutics, LLC | Initial Phase 2b Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine... eliostherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLPLDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02301611 ↗ |
| Modality | Vaccine | “The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine” PMID 39305541 ↗ Sep 2024 |
| Route | Other | “TLPLDC are injected intradermally (ID) monthly x 3” NCT02301611 ↗ |